Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-κB ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone resorption, plays a major role in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with bone loss. Denosumab inhibits the action of RANKL, thereby reducing the differentiation, activity, and survival of osteoclasts, and lowering the rate of bone resorption. Clinical trials have shown that denosumab increases bone mineral density (BMD) and reduces bone turnover in postmenopausal women with low BMD. Studies to evaluate the fracture risk benefit and long-term safety of denosumab in women with postmenopausal osteoporosis (PMO) are ongoing. Denosumab is a potential treatment for PMO and other skeletal disorders

Lewiecki, E Michael

English

PubMed

E Michael LewieckiNew Mexico Clinical Research &amp;amp; Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-&amp;kappa;B ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone resorption, plays a major role in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with bone loss. Denosumab inhibits the action of RANKL, thereby reducing the differentiation, activity, and survival of osteoclasts, and lowering the rate of bone resorption. Clinical trials have shown that denosumab increases bone mineral density (BMD) and reduces bone turnover in postmenopausal women with low BMD. Studies to evaluate the fracture risk benefit and long-term safety of denosumab in women with postmenopausal osteoporosis (PMO) are ongoing. Denosumab is a potential treatment for PMO and other skeletal disorders.Keywords: osteoporosis, treatment, denosumab, AMG 162, RANKL, OP

E Michael Lewiecki

Directory of Open Access Journals

Biologics Targets and Therapy

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

A comparison of denosumab and alendronate in combination with PTH in ovariectomized knockin mice expressing humanized RANKL. J Bone Miner Res,

A phase I study of AMGN0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.

A systematic review of persistence and compliance with bisphosphonates for osteoporosis.

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Antibody pharmacokinetics and pharmacodynamics.

Assessment of fracture risk. Osteoporos Int,

Bone Health and Osteoporosis: A Report of the Surgeon General.

Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures – A gap in evidence-based practice guideline implementation.

CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin.

Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1–34).

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA, 292:490–5.Biologics: Targets & Therapy 2008:2(4) 653 Denosumab for osteoporosis Hofbauer LC,

Compliance with drug therapies for the treatment and prevention of osteoporosis.

Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int,

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.

Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int,

Denosumab (AMG 162), a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res,

Denosumab in postmenopausal women with low bone mineral density.

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial.

Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.

Fracture risk following an osteoporotic fracture. Osteoporos Int,

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.

How many women have osteoporosis now?

Incidence and economic burden of osteoporosis-related fractures in the United States,

Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc,

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

OPG and PTH-(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.

Osteoclast differentiation and activation.

Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

Osteoclast precursors, RANKL/ RANK, and immunology. Immunol Rev,

Osteoporosis prevention, diagnosis, and therapy.

Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.

Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum,

osteoprotegerin-deﬁ cient mice develop early onset osteoporosis and arterial calciﬁ cation. Genes Dev,

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Perspective. How many women have osteoporosis? J Bone Miner Res,

Pharmacokinetic aspects of biotechnology products.

Phase 2 study of denosumab (AMG 162) in postmenopausal women: subanalyses and supplemental safety. J Bone Miner Res,

Randomized active-controlled phase ii study of denosumab efﬁ cacy and safety in patients with breast cancer-related bone metastases.

RANK is essential for osteoclast and lymph node development.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

RANKL inhibition with (denosumab) AMG 162, a fully human MAb, causes sustaned suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Miner Res,

Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum,

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res,

Regulation of vascular calciﬁ cation by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res,

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reﬂ ected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1–34) and hPTH-(1–84). Endocrinology,

The crippling consequences of fractures and their impact on quality of life.

The effect of a single dose of osteoprotegerin in postmenopausal women.

The effects of osteoprotegerin on the mechanical properties of rat bone.

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

The long and the short of bone therapy.

The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res,

The RANK/RANKL/ osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum,

The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev,

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-speciﬁ c survival factor.

TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells.

Tumor necrosis factor alphamediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum,

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2727882

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals